Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis

Q: What is the CRNX stock price target?

Take-profit $72.52 (+91.4% upside). Prior stop was $35.24.

Q: What are the risks of investing in CRNX?

Concentration risk — Product: PALSONIFY; Quality below floor (1.5 < 4.0); Quality below floor (1.5 < 4.0); Momentum score 3.9/10 — below 4.5 minimum.

Q: Is CRNX overvalued or undervalued?

Crinetics Pharmaceuticals, Inc. trades at a P/E of N/A (forward -9.4). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about CRNX?

22 analysts cover CRNX with a consensus score of 4.2/5. Average price target: $83.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Crinetics Pharmaceuticals is a commercial-stage pharmaceutical company focused on endocrine diseases, with PALSONIFY (paltusotine) FDA-approved in September 2025 as the first once-daily oral treatment for acromegaly. Revenue is from PALSONIFY sales launched October 2025 in the... Read more

$37.77+91.4% A.UpsideScore 4.9/10#88 of 158 Biotechnology

Stop $35.24Target $72.52(analyst − 13%)A.R:R 11.3:1

Analyst target$83.36+120.7%14 analysts

$72.52our TP

$37.77price

$83.36mean

$97

Sell if holding. Engine safety override at $37.77: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 11.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.39; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.

Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Product: PALSONIFY

Quality below floor (1.5 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-9.4

Mkt Cap$4.0B

EV/EBITDA-5.9

Profit Mgn0.0%

ROE-40.2%

Rev Growth—

Beta0.31

DividendNone

Rating analysts22

Quality Signals

Piotroski F2/9

Options Flow

P/C1.39bearish

IV78%elevated

Max Pain$25-33.8% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductPALSONIFY
10-K Item 1A: 'our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful commercialization of PALSONIFY'

Material Events(8-K, last 90d)

2026-03-03Item 4.01HIGH
BDO USA, P.C. dismissed as independent registered public accounting firm on February 27, 2026. No disagreements with BDO on accounting matters. No new auditor named in filing.
SEC filing →
2026-03-23Item 5.02LOW
Jeff Knight notified CRNX of resignation as Chief Development and Operating Officer effective ~April 10, 2026, to pursue another opportunity. All managerial responsibilities reassigned to other executive leadership. No disagreement cited.
SEC filing →
2026-04-10Item 5.02LOW
Jeff Knight's CDOO resignation became effective April 10, 2026. Company entered 1-year consulting agreement with Knight at $400/hr (max 20 hrs/month) for operational and clinical development matters.
SEC filing →
2026-01-26Item 5.02LOW
Jeff Knight's title changed from Chief Operating Officer to Chief Development and Operating Officer effective January 2, 2026. No compensation change. No successor named as no vacancy created.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·2 ceiling hits

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.515%0.22

Growth5.015%0.75

Momentum3.910%0.39

Sentiment8.810%0.88

Insider Activity3.310%0.33

Peer Rank3.910%0.39

Technical Setup5.75%0.29

Risk Profile3.25%0.16

Catalyst3.25%0.16

Overall (Σ contributions)4.92

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -2689% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

News Activity

6.0

Earnings concerns: 1B/3MEarnings in 7 days

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.0

Ma Position

2.2

Macd

2.6

Rsi

4.5

Obv

10.0

Volume accumulation (rising OBV)Below 200-MA but MA still rising (+2.5%/30d) — pullback in uptrend, not confirmed weakness

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

3.5

Value Rank

5.0

Growth Rank

5.0

GatesMomentum 3.9<4.5EARNINGS PROXIMITY 7d<=7dA.R:R 11.3 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

42 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $35.83Resistance $41.33

Price Targets

$35

$73

A.Upside+92.0%

A.R:R11.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.5 < 4.0)

! Momentum score 3.9/10 — below 4.5 minimum

! EARNINGS_PROXIMITY:7d<=7d

Earnings

1/4 beats

Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is CRNX stock a buy right now?

Sell if holding. Engine safety override at $37.77: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 11.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.39; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $35.24. Score 4.9/10, moderate confidence.

What is the CRNX stock price target?

Take-profit target: $72.52 (+91.4% upside). Prior stop was $35.24. Stop-loss: $35.24.

What are the risks of investing in CRNX?

Concentration risk — Product: PALSONIFY; Quality below floor (1.5 < 4.0).

Is CRNX overvalued or undervalued?

Crinetics Pharmaceuticals, Inc. trades at a P/E of N/A (forward -9.4). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about CRNX?

22 analysts cover CRNX with a consensus score of 4.2/5. Average price target: $83.

What does Crinetics Pharmaceuticals, Inc. do?Crinetics Pharmaceuticals is a commercial-stage pharmaceutical company focused on endocrine diseases, with PALSONIFY...